par MEDIAN TECHNOLOGIES (EPA:ALMDT)
Changes in the rights attaching to the classes of shares or securities
Press release – For immediate release September 6, 2024 – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of August 3[1]st, 2024
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Sophia Antipolis, France
Total number of shares | 18,448,233 |
Number of real voting rights* (excluding treasury shares**) | 18,363,983 |
Theoretical number of voting rights* (including treasury shares**) | 18,425,033 |
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on
the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Contacts
Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com | Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com | Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ghislaine.gasparetto@seitosei-actifin.com |